DaVita
DVA
$217.04
+1.72%
DaVita Inc. is the largest provider of dialysis services in the United States, operating over 3,000 facilities globally and treating approximately 280,000 patients annually within the healthcare sector's medical care facilities industry. The company's competitive identity is defined by its dominant market share of about 35% by clinics, operating a highly regulated, asset-intensive business model where profitability is heavily concentrated in its commercial insurance payer segment despite government payers like Medicare constituting the majority of revenue. The current investor narrative centers on the stock's dramatic price appreciation, which has significantly outpaced the broader market, likely driven by strong operational execution, robust free cash flow generation enabling aggressive share repurchases, and a reassessment of its stable, recession-resilient business model in a volatile economic environment.…
DVA
DaVita
$217.04
Related headlines
DVA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $282.15 and implied upside of +30.0% versus the current price.
Average Target
$282.15
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$174 - $282
Analyst target range
Analyst coverage for DaVita appears limited, with only 2 analysts providing estimates for revenue and EPS, indicating this may be a under-followed name among institutional investors, which can lead to higher volatility and less efficient price discovery. The available data shows estimated EPS for the next period has a wide range from $17.72 to $18.77, with an average of $18.12, and estimated revenue ranges from $15.63 billion to $16.34 billion, averaging $15.89 billion; this wide dispersion in targets signals significant uncertainty or differing views on the company's near-term prospects. Recent institutional ratings from firms like Barclays (Equal Weight), UBS (Buy), and B of A Securities (Underperform) show a lack of consensus, with actions primarily being reiterations, suggesting analysts are in a 'wait-and-see' mode following the stock's major re-rating, awaiting clearer fundamental catalysts or policy developments.
Bulls vs Bears: DVA Investment Factors
The bull case, supported by strong operational execution, massive free cash flow, and a reasonable valuation despite the rally, currently holds stronger evidence. The bear case centers on financial leverage, margin volatility, and the stock's technical overextension after a parabolic move. The single most important tension in the investment debate is whether the company's exceptional free cash flow generation and shareholder returns can sustainably outweigh the risks posed by its highly leveraged balance sheet and dependence on favorable regulatory and payer dynamics. The resolution of this tension—specifically, the market's long-term comfort with the leverage versus its appreciation of the cash returns—will determine the stock's trajectory.
Bullish
- Exceptional Free Cash Flow Generation: DaVita generates robust free cash flow, with TTM FCF of $1.31 billion. This strong cash generation funds aggressive shareholder returns, evidenced by $759.1 million in share repurchases in Q4 2025 alone, directly supporting the stock price.
- Strong Revenue Growth & Market Dominance: The company reported solid 9.87% YoY revenue growth in Q4 2025, reaching $3.62 billion. As the largest U.S. dialysis provider with ~35% market share, its essential-service model provides a stable, recession-resilient revenue base.
- Attractive Valuation Despite Price Rally: Despite a 53% 1-year price surge, DVA trades at a trailing PE of 13.10x and a forward PE of 12.10x. This valuation is not stretched relative to its own history and offers a discount to many healthcare peers, suggesting room for multiple expansion.
- Powerful Technical Momentum & Outperformance: The stock has dramatically outperformed the market, with a 6-month return of +80.48% and a 1-year return of +53.11% vs. the S&P 500. Trading at 97% of its 52-week high ($213.44), it demonstrates strong bullish momentum and investor conviction.
Bearish
- Highly Leveraged & Distorted Balance Sheet: The company carries a negative Debt-to-Equity ratio of -23.12 and a negative ROE of -114.70%, indicating a significant shareholder deficit. While operational cash flow is strong, this accounting leverage presents a financial risk and valuation headwind.
- Profitability Volatility & Margin Pressure: Net income declined from $259.33 million in Q4 2024 to $234.22 million in Q4 2025, despite revenue growth, indicating margin pressure. The net margin of 6.47% and gross margin of 28.28% show sensitivity to cost increases and reimbursement rates.
- Limited Analyst Coverage & Lack of Consensus: Only 2 analysts provide estimates, indicating the stock is under-followed, which can lead to inefficient price discovery and higher volatility. Recent institutional ratings show a lack of consensus (Equal Weight, Buy, Underperform), creating uncertainty.
- Extreme Price Run-Up & Technical Overextension: Trading at $207.91, the stock is just 2.6% below its 52-week high after an 80% 6-month surge. This parabolic move raises concerns of a near-term consolidation or pullback, as the price may be overextended relative to its immediate fundamental progress.
DVA Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +53.11% and a 6-month surge of +80.48%, dramatically outperforming the S&P 500. As of the latest close of $207.91, the price is trading near the top of its 52-week range, approximately 97% of the way towards its 52-week high of $213.44, indicating strong momentum but also raising concerns about potential overextension and limited near-term upside before encountering significant resistance. Recent momentum remains robust but shows signs of consolidation; the stock gained 6.83% over the past month and 39.25% over three months, though the 1-month gain is notably lower than the explosive 3-month return, suggesting the rally may be entering a phase of digestion after the steep ascent from below $150 in early February to above $200 by May. Key technical support is anchored at the 52-week low of $101.00, while immediate resistance sits at the 52-week high of $213.44; a decisive breakout above this level could signal a continuation of the bull trend, whereas a failure and reversal could indicate a double-top formation and a significant pullback. With a beta of 0.908, DaVita exhibits slightly lower volatility than the broader market, which is atypical for a stock with such explosive recent returns and suggests its price movements have been driven by strong fundamental catalysts rather than speculative beta-driven swings.
Beta
0.91
0.91x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$101-$217
Price range past year
Annual Return
+53.8%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +11.3% | -2.9% |
| 3m | +40.5% | +15.0% |
| 6m | +90.4% | +5.6% |
| 1y | +53.8% | +19.1% |
| ytd | +89.5% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
Revenue growth is stable and positive, with Q4 2025 revenue of $3.62 billion representing a solid 9.87% year-over-year increase, and the sequential trend from Q1 to Q4 2025 shows consistent quarterly revenue growth from $3.22 billion to $3.62 billion. The company's U.S. Dialysis and Related Lab Services segment, generating $10.12 billion annually, is the sole and dominant driver of this growth, underpinned by its essential-service model. DaVita is solidly profitable, reporting Q4 2025 net income of $234.22 million and a net margin of 6.47%, supported by a gross margin of 28.28%; however, profitability has shown some quarterly volatility, with net income declining from $259.33 million in Q4 2024, indicating potential margin pressure or increased costs. The balance sheet and cash flow position are a study in contrasts: the company generates exceptionally strong free cash flow, with TTM free cash flow of $1.31 billion, funding aggressive share repurchases (evidenced by $759.1 million in buybacks in Q4 2025 alone), but it carries a highly leveraged capital structure with a negative debt-to-equity ratio of -23.12 and a negative Return on Equity of -114.70%, which are accounting artifacts stemming from significant shareholder deficits rather than operational insolvency, as the robust current ratio of 1.29 and substantial operating cash flow demonstrate ample liquidity to service obligations.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Given DaVita's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 13.10x and a forward PE of 12.10x based on estimated EPS; the modest discount of the forward multiple suggests the market anticipates stable, but not dramatically accelerating, earnings growth. Compared to sector averages, DaVita's valuation presents a mixed picture: its trailing PE of 13.10x is likely at a discount to many high-growth healthcare peers but may be in line with regulated service providers, while its Price-to-Sales ratio of 0.72x and EV-to-Sales of 2.01x appear low, potentially indicating the market assigns a lower multiple due to its leveraged balance sheet and regulatory exposure. Historically, the current trailing PE of 13.10x sits well below the stock's own historical range observed in the data, which has seen periods with PEs above 15x and even negative equity-based multiples (like PB ratio), suggesting that despite the massive price rally, the valuation on an earnings basis is not stretched relative to its own history and may have room for expansion if leverage concerns abate and cash flow sustainability is confirmed.
PE
11.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: DaVita's primary financial risk stems from its highly leveraged capital structure, evidenced by a negative Debt-to-Equity ratio of -23.12 and negative shareholder equity. While robust operating cash flow ($1.31B TTM FCF) services debt, this structure limits financial flexibility and amplifies downside risk if reimbursement rates fall or costs rise. Profitability is volatile, with Q4 2025 net income down 9.7% YoY despite revenue growth, indicating margin pressure from rising SG&A (up 14% in Q4 YoY). The business model is critically dependent on commercial insurance payers for nearly all profits, despite them constituting only ~10% of patients, creating extreme revenue concentration risk.
Market & Competitive Risks: The stock's dramatic 80% 6-month surge has pushed it to trade at 97% of its 52-week high, creating valuation compression risk if growth expectations moderate. Trading at a forward PE of 12.1x, it may be fairly valued relative to its regulated, asset-intensive sector, but a sector rotation away from defensive healthcare could pressure multiples. The core business faces perpetual regulatory risk from Medicare reimbursement changes, which dictate the economics for the majority of its revenue. Competitive disruption is limited due to high barriers to entry, but pricing pressure from insurers and potential government intervention in dialysis pricing remain persistent external threats.
Worst-Case Scenario: A worst-case scenario involves a simultaneous negative Medicare reimbursement update, a sharp decline in the commercial insured patient mix, and a broader market downturn compressing valuations. This could trigger a significant earnings miss, leading to analyst downgrades and a rapid de-rating. The realistic downside could see the stock re-test its 52-week low of $101.00, representing a potential loss of approximately -51% from the current price of $207.91. The historical max drawdown of -31.36% provides a reference, but given the recent parabolic rise, a mean-reversion pullback could be more severe if sentiment shifts abruptly.